# A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)

> **NCT01115556** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vitreous -Retina- Macula Consultants of New York** · enrollment: 9 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** Ranibizumab
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT01115556
- **Lead sponsor:** Vitreous -Retina- Macula Consultants of New York
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2018-05-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01115556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01115556, "A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01115556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*